Phaseline

Targets › FAM19A5

FAM19A5 (Chemokine-like protein TAFA-5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other.

Acts as a chemokine-like protein by regulating cell proliferation and migration through activation of G protein-coupled receptors (GPCRs), such as S1PR2 and FPR2 (By similarity). Stimulates chemotactic migration of macrophages mediated by the MAPK3/ERK1 and AKT1 pathway (By similarity). (UniProt, Q7Z5A7)

Open in Phaseline: the race on FAM19A5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neuracle ScienceNS101
anti-FAM19A5 antibody; synapse organizer and reverser of synapse dysfunction
FAM19A5Phase 1Seneorineural Deafness–

Conditions

Seneorineural Deafness (1)

Modalities

protein or peptide (1)

Companies

Neuracle Science (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.